3 results
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Although these products have been used extensively in patients, the effect of these medications on experimental pain sensation has never been investigated. There is little knowledge about any direct effect of these medications on pain perception. In…
Primary Objective: to study the feasibility, effectiveness and user experience of the Parkinson smartwatch in Parkinson patients with response fluctuations (with dyskinesia).Secondary Objective(s): to study the effect on cost, by monitoring the…